Dry eye renaissance: Escalating cases meet with innovation

News
Article
Ophthalmology Times EuropeOphthalmology Times Europe October 2023
Volume 19
Issue 08
Pages: 24 - 26

For clinicians, the evolution of treatment is as much a responsibility as an opportunity

Two decades ago, managing dry eye disease was straightforward. Practitioners were able to offer a few options: artificial tears, prescription cyclosporine ophthalmic emulsion (Restasis; Allergan), and punctal occlusion.

Since then, our options have multiplied. With novel treatments and diagnostics, we’ve entered an era of innovative management for this common condition—a kind of dry eye renaissance.

David Wirta, MD, left, and George N. Magrath, MD, MBA, MS, right

David Wirta, MD, left, and George N. Magrath, MD, MBA, MS, right

Progress is essential because dry eye’s incidence is growing. Partly attributable to increased diagnostic skill, the spike is also driven by our population’s advancing age, irritants such as contact lens wear and extended screen time,1 and an awareness among patients that they don’t have to live with scratchiness, burning or blurred vision. Results from a large US study confirmed this escalation, showing an increase in dry eye’s overall prevalence, annual prevalence and incidence between 2003 and 2015.2

Fortunately, we now have the power to respond to this trend thoughtfully and comprehensively. Today, we can identify and address not only the symptoms of dry eye but its causes. We can reach patients who are uninsured or underinsured with an affordable generic formulation of Restasis.3 And we can improve the calibre of clinical trials by using precision diagnostics to standardise end point analyses.

For clinicians, the evolution of dry eye management is as much a responsibility as an opportunity. Only by staying informed about the growing spectrum of products can we do our best to manage this intractable condition.

Treatment timeline

Since Restasis was introduced in 2003, anti-inflammatory drops have been at the heart of dry eye management. Over the past 7 years, the category has diversified with FDA approvals of a high-concentration cyclosporine ophthalmic solution (Cequa; Sun Ophthalmics); lifitegrast ophthalmic solution (Xiidra; Novartis), an antagonist that blocks LFA-1; and loteprednol etabonate ophthalmic suspension (Eysuvis; Kala Pharmaceuticals), a topical corticosteroid.

But the latest treatments don’t address inflammation, focusing instead on other drivers of dry eye. The nasal spray varenicline solution (Tyrvaya; Viatris) is a partial nicotinic receptor agonist that stimulates the secretory nerves, causing the release of aqueous from the lacrimal gland to stimulate the production of tears. Perfluorohexyloctane ophthalmic solution (Miebo; Bausch + Lomb, Novaliq), approved in May 2023, is a nonaqueous topical that prevents tears from evaporating. In two large phase three trials, the drug significantly reduced the signs and symptoms of dry eye in patients with a history of the condition and clinical indications of meibomian gland dysfunction.4

Cyclosporine ophthalmic solution (Vevye; Novaliq), formerly CyclASol, was approved in June 2023. Free of water, preservatives, oils, and surfactants, cyclosporine ophthalmic solution is designed to offer early and durable efficacy for patients.

Of course, medications are not the only option for managing meibomian gland dysfunction. FDA-approved devices include OptiLight (Lumenis), which uses intense pulsed light therapy; LipiFlow (Johnson & Johnson Vision), a thermal pulsation system; iLux (Alcon), which applies compression and light-based heat; and the TearCare System (Sight Sciences) for heat and gland expression.

Additional treatments with unique mechanisms are on the horizon. Topical formulations being investigated in phase three clinical trials include:

  • BRM421 (BRIM Biotechnology), a synthetic peptide that sparks tissue regeneration and corneal repair, reduces inflammation, and improves tear quality
  • Reproxalap (Aldeyra Therapeutics), a reactive aldehyde species inhibitor that reduces inflammation
  • SI-614 (Seikagaku), a modified hyaluronate that stabilises the tear film and promotes corneal wound healing
  • Tivanisiran (Sylentis), a small interfering RNA that controls pain and inflammation by inhibiting the synthesis of TRPV1
  • Visomitin (Mitotech), a cardiolipin peroxidation inhibitor that sustains and restores mitochondrial function to target inflammation, corneal damage, tear deficiency, and gland tissue regeneration
Figure 1 displays corneal staining. Image courtesy of David Wirta, MD

Figure 1. Corneal staining.
(Image courtesy of David Wirta, MD)

Diagnosis precision

Without precise diagnostic tools, practitioners would be unable to provide personalised treatment. The old standby is the Schirmer test, which determines whether eyes are underproducing or overproducing tears. But tear film can now be analysed with InflammaDry (Quidel), which detects an inflammation-linked enzyme, MMP-9, to identify patients who may benefit from anti-inflammatory therapy. Also available are the ATD TearScan 300 microassay (Advanced Tear Diagnostics), which identifies dry eye by measuring lactoferrin and IgE levels in tears, and the Osmolarity System (TearLab), which measures the aqueous content of the tear film by checking for heightened electrolytes.

Experimental diagnostics are promising. TeaRx technology (DiagnosTear) performs a multiparameter assay on a tiny tear sample to make a differential dry eye diagnosis. This 10-minute assay could become the first available at the point of care.

Other strategies may help standardise clinical trials. BEDx (Boston Eye Diagnostics) is an imaging technology that captures clear photographs of corneas stained with fluorescein and other images of the ocular surface. In an automated and repeatable manner, the device takes several pictures and volume averages them to create an image that is in focus across multiple depths. The system’s objectivity may level the grading of corneal staining photos.

Standardised grading may also be supported by a modified version of the National Eye Institute’s corneal fluorescein staining scale (Figure). In a recent study, researchers at Lexitas introduced a modified scale to support more reliable and repeatable assessment methodology for examiners.5

A practice-changing trend

The dry eye renaissance has changed not only our armamentarium but the way we provide care. Because managing the condition is often time consuming, many practices are opening dry eye centres6 that accommodate diagnosis and treatment without affecting other clinic scheduling. Their services include cash pay therapies such as LipiFlow, vitamins and artificial tears for patients seeking care beyond what their insurance will cover. Cataract surgeons have also focused on dry eye management,7 because resolving symptoms before a procedure can support the accuracy of refractive calculations and limit postsurgical discomfort.

There’s no doubt that advances in dry eye management and diagnosis are making a difference for patients, but questions remain. Can issues such as diet8 and climate exacerbate dry eye? Should lifestyle recommendations such as better hydration and turning off ceiling fans be part of our treatment plans? Answers are sure to emerge as we pursue further research, building on today’s advances with next-level discoveries about this multifactorial condition.

References

1. Karmel M. A quick guide to dry eye. American Academy of Ophthalmology. June 2014. Accessed 9 June, 2023. https://www.aao.org/eyenet/article/quick-guide-to-dry-eye
2. Dana R, Bradley JL, Guerin A, et al. Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States health care system. Am J Ophthalmol. 2019;202:47-54. doi:10.1016/j.ajo.2019.01.026
3. FDA approves first generic of Restasis. News release. FDA. February 2, 2022. Accessed 9 June, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-restasis
4. Bausch + Lomb and Novaliq announce FDA approval of MIEBO (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease. News release. Bausch + Lomb. 18 May, 2023. Accessed 9 June, 2023. https://tinyurl.com/559t9pxv
5. Sall K, Foulks GN, Pucker AD, Ice KL, Zink RC, Magrath G. Validation of a modified National Eye Institute grading scale for corneal fluorescein staining. Clin Ophthalmol. 2023;17:757-767. doi:10.2147/OPTH.S398843
6. Cole J. How to build a dry eye center of excellence. Review of Optometry. 14 September, 2014. Accessed 9 June, 2023. https://www.reviewofoptometry.com/article/ro0914-how-to-build-a-dry-eye-center-of-excellence
7. Mukamal R. Don’t let dry eye derail cataract surgery. American Academy of Ophthalmology. 20 May, 2022. Accessed 9 June, 2023. https://www.aao.org/eye-health/tips-prevention/dry-eye-cataract-surgery-ocular-surface-disease
8. Sanford K. Diet: why dry eye hangs in the balance. Review of Optometry. 15 May, 2020. Accessed 9 June, 2023. https://www.reviewofoptometry.com/article/diet-why-dry-eye-hangs-in-the-balance
Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.